MX2018005046A - Metodo para producir flutemetamol. - Google Patents

Metodo para producir flutemetamol.

Info

Publication number
MX2018005046A
MX2018005046A MX2018005046A MX2018005046A MX2018005046A MX 2018005046 A MX2018005046 A MX 2018005046A MX 2018005046 A MX2018005046 A MX 2018005046A MX 2018005046 A MX2018005046 A MX 2018005046A MX 2018005046 A MX2018005046 A MX 2018005046A
Authority
MX
Mexico
Prior art keywords
flutemetamol
general formula
above step
labeling compound
predetermined general
Prior art date
Application number
MX2018005046A
Other languages
English (en)
Inventor
Okumura Yuki
Tonoya Gota
Matsunami Tomoyuki
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of MX2018005046A publication Critical patent/MX2018005046A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Saccharide Compounds (AREA)
  • Ink Jet (AREA)

Abstract

Se proporciona un método para producir flutemetamol que incluye las etapas de: hacer reaccionar un compuesto precursor representado por una fórmula general predeterminada con un fluoruro radioactivo para obtener un compuesto etiquetado 18F representado por una fórmula general predeterminada; permitir una base fuerte para actuar sobre la mezcla de reacción de la etapa de arriba que contiene el compuesto precursor y el compuesto etiquetado 18F; después de la etapa de arriba, purificar el compuesto etiquetado 18F utilizando un cartucho de extracción de fase sólida de fase inversa; y remover un grupo protector para obtener [18F]flutemetamol.
MX2018005046A 2015-10-28 2016-10-17 Metodo para producir flutemetamol. MX2018005046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015211413A JP6485914B2 (ja) 2015-10-28 2015-10-28 フルテメタモルの製造方法
PCT/EP2016/074840 WO2017071980A1 (en) 2015-10-28 2016-10-17 Method for producing flutemetamol

Publications (1)

Publication Number Publication Date
MX2018005046A true MX2018005046A (es) 2018-06-13

Family

ID=57144967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005046A MX2018005046A (es) 2015-10-28 2016-10-17 Metodo para producir flutemetamol.

Country Status (12)

Country Link
US (1) US10472338B2 (es)
EP (1) EP3368518B1 (es)
JP (1) JP6485914B2 (es)
CN (1) CN108137520B (es)
AU (1) AU2016344537B2 (es)
CA (1) CA2998985C (es)
ES (1) ES2766474T3 (es)
HK (1) HK1249098A1 (es)
IL (1) IL258148B (es)
MX (1) MX2018005046A (es)
RU (1) RU2733398C2 (es)
WO (1) WO2017071980A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6485914B2 (ja) 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法
JP6770837B2 (ja) * 2016-06-28 2020-10-21 日本メジフィジックス株式会社 放射性フッ素標識有機化合物を製造する方法
CN110809575A (zh) 2017-06-23 2020-02-18 日本医事物理股份有限公司 放射性卤素标记化合物的制造方法及放射性医药的制造方法
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1010280A3 (fr) * 1996-05-02 1998-05-05 Coincidence S A Procede et dispositif de synthese de 2-[18f] fluoro-2-deoxy-d-glucose.
GB0229686D0 (en) * 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
WO2006133732A1 (en) * 2005-06-17 2006-12-21 Advanced Accelerator Applications Process for synthesizing labelled compounds
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
JP4550141B2 (ja) * 2006-05-11 2010-09-22 日本メジフィジックス株式会社 放射性フッ素標識有機化合物の製造方法
CA2694084C (en) 2007-08-30 2015-07-07 Ge Healthcare Limited Radiopharmaceutical composition
PL2509637T3 (pl) * 2009-10-08 2016-12-30 Sposób oczyszczania
JP6485914B2 (ja) 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法

Also Published As

Publication number Publication date
JP2017081847A (ja) 2017-05-18
AU2016344537A1 (en) 2018-04-12
RU2018113741A3 (es) 2020-02-20
RU2733398C2 (ru) 2020-10-01
IL258148A (en) 2018-05-31
KR20180073581A (ko) 2018-07-02
BR112018007545A2 (pt) 2018-10-23
CA2998985C (en) 2023-10-31
EP3368518B1 (en) 2019-12-04
HK1249098A1 (zh) 2018-10-26
US10472338B2 (en) 2019-11-12
IL258148B (en) 2020-08-31
CN108137520B (zh) 2022-06-21
ES2766474T3 (es) 2020-06-12
WO2017071980A1 (en) 2017-05-04
CA2998985A1 (en) 2017-05-04
CN108137520A (zh) 2018-06-08
AU2016344537B2 (en) 2020-09-17
JP6485914B2 (ja) 2019-03-20
US20190055207A1 (en) 2019-02-21
EP3368518A1 (en) 2018-09-05
RU2018113741A (ru) 2019-11-28

Similar Documents

Publication Publication Date Title
MX2018005046A (es) Metodo para producir flutemetamol.
NZ705827A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
EP4279535A3 (en) Method for preparing polyols
NZ734535A (en) Process of producing cycloalkylcarboxamido-indole compounds
MX353553B (es) Metodo para producir derivados de 4,4-difluoro-3,4-dihidroisoquino lina.
MX2016011527A (es) Metodo para recuperacion de vanadio y tungsteno a partir de una solucion de lixiviacion del catalizador de desnitrificacion de desecho.
AR076974A1 (es) Metodo para sintetizar pirfenidona
MY158251A (en) Method for the preparation of nalmefene hydrochloride
WO2011087316A3 (ko) 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
WO2016073425A3 (en) Method for preparing deuterated aromatic compounds
WO2013002486A3 (ko) 고상 반응에 의한 리튬 망간 산화물의 제조 방법
UA117984C2 (uk) Спосіб і установка для витягання радіоактивних нуклідів з відпрацьованих смоляних матеріалів
WO2012081880A3 (ko) 18f 방사성의약품 제조를 위한 고체 지지체에 연결된 전구체 화합물, 이의 제조방법 및 응용
PH12014502779B1 (en) Preparation method for perfluoro-2-methyl-3-pentanone and intermediate
IN2014DN09053A (es)
IN2014DN00144A (es)
GB201210256D0 (en) Improved butanol recovery process
MX2016016730A (es) Metodo para preparar un producto intermedio de eribulina.
WO2014115174A8 (en) Novel approach for synthesis of catechins
MX2016001199A (es) Proceso para preparar rifaximina kappa.
WO2012164242A8 (en) Process for the preparation of paliperidone
PH12014502495A1 (en) Method for producing refined glycerin alkyl ether
MX2020001448A (es) Proceso para convertir monourea ciclica de un compuesto de etilenamina en un compuesto etilenaminico.
CL2014002029A1 (es) Método para preparar un compuesto de formula 1 mediante la reacción de adición de michael , usando agua o acido o una mezcla de los mismos como aditivo, entre un compuesto de formula 2 y un compuesto de formula 3 en presencia de polvo de cobre.
NZ630569A (en) Process for the purification of diaminophenothiazinium compounds

Legal Events

Date Code Title Description
FG Grant or registration